Non-relapse mortality

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06